Chimeric Anti-PDPN Antibody ChLpMab-2
Kaneko, Mika K. Tohoku University
Yamada, Shinji Tohoku University
Nakamura, Takuro Tohoku University
Abe, Shinji Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Nishioka, Yasuhiko Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Kunita, Akiko The University of Tokyo
Fukayama, Masashi The University of Tokyo
Fujii, Yuki Tohoku University
Ogasawara, Satoshi Tohoku University|Chiba University
Kato, Yukinari Tohoku University|Tohoku University|New Industry Creation Hatchery Center
Antibody-dependent cellular cytotoxicity
Human podoplanin (hPDPN ), a platelet aggregation‐inducing transmembrane glycoprotein, is expressed in different types of tumors, and it binds to C‐type lectin‐like receptor 2 (CLEC ‐2). The overexpression of hPDPN is involved in invasion and metastasis. Anti‐hPDPN monoclonal antibodies (mAbs) such as NZ ‐1 have shown antitumor and antimetastatic activities by binding to the platelet aggregation‐stimulating (PLAG ) domain of hPDPN . Recently, we developed a novel mouse anti‐hPDPN mAb, LpMab‐2, using the cancer‐specific mAb (CasMab) technology. In this study we developed chLpMab‐2, a human–mouse chimeric anti‐hPDPN antibody, derived from LpMab‐2. chLpMab‐2 was produced using fucosyltransferase 8‐knockout (KO ) Chinese hamster ovary (CHO )‐S cell lines. By flow cytometry, chLpMab‐2 reacted with hPDPN ‐expressing cancer cell lines including glioblastomas, mesotheliomas, and lung cancers. However, it showed low reaction with normal cell lines such as lymphatic endothelial and renal epithelial cells. Moreover, chLpMab‐2 exhibited high antibody‐dependent cellular cytotoxicity (ADCC ) against PDPN ‐expressing cells, despite its low complement‐dependent cytotoxicity. Furthermore, treatment with chLpMab‐2 abolished tumor growth in xenograft models of CHO /hPDPN , indicating that chLpMab‐2 suppressed tumor development via ADCC . In conclusion, chLpMab‐2 could be useful as a novel antibody‐based therapy against hPDPN ‐expressing tumors.
John Wiley & Sons
© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
|DOI (Published Version)|
|URL ( Publisher's Version )|
cam_6_4_768.pdf 519 KB